Rosen Quoted on Research Firm Asking FDA to Clear Path for Generic Fosamax
July 3, 2014
Law360
Partner David Rosen was quoted in a Law360 article published on July 3, 2014, titled “Research Firm Asks FDA to Clear Path for Generic Fosamax.” The article discussed a citizen petition made by the research firm Clinipace Worldwide asking the U.S. Food and Drug Administration to issue a finding that Merck & Co. did not discontinue the osteoporosis drug Fosamax for health and safety reasons. Rosen was quoted saying, “There have been relatively few instances where the FDA has withdrawn the reference listed drug for reasons related to safety or effectiveness.”
People
Related News
May 28, 2025
In the News
Cliff Risman Featured on Hospitality Trends – Transactions at 'almost historic levels'
Foley & Lardner LLP partner Cliff Risman is featured in the Law360 Q&A, "Foley Hospitality Leader Talks Deals In Economic Uncertainty."
May 27, 2025
In the News
Kyle Faget Profiled on Health Care Evolution – 'Only just beginning to see what's possible'
Foley & Lardner LLP partner Kyle Faget is profiled by The Inspirational Leaders for her achievements and vision in health care law.
May 27, 2025
In the News
Foley's Silicon Valley Corporate Additions Featured in Legal Press
Foley & Lardner LLP partners Gurpreet Bal and Shaalu Mehra are highlighted in legal press for their recent arrival to the firm.